Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.46 |
| ▸ | TLR2 | O60603 | 3/20 | 0.43 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153101 | 0.92 | DNM1 (0.49) | EPHX2DNM1BLMPMP22HSD17B10 | |
| SCHEMBL13934645 | 0.85 | DNM1 (0.42) | EPHX2DNM1CA1CA2BLM | |
| Glycol Distearate SCHEMBL1527579 | 0.85 | DGKA (0.68) | DGKADNM1TLR2PAMBLM | |
| SCHEMBL14252347 | 0.84 | BLM (0.46) | CA1CA2BLMPMP22HSD17B10 | |
| SCHEMBL9425809 | 0.82 | DGKA (0.64) | DGKAEPHX2DNM1GLP1RL3MBTL1 | |
| SCHEMBL10251463 | 0.82 | EPHX2 (0.49) | DGKAEPHX2DNM1PAML3MBTL1 | |
| SCHEMBL6047711 | 0.82 | ALDH1A1 (0.45) | EPHX2CA1CA2BLMPMP22 | |
| SCHEMBL3153992 | 0.80 | TSHR (0.44) | EPHX2CA1CA2BLMPMP22 | |
| SCHEMBL9276251 | 0.80 | DGKA (0.59) | DGKADNM1TLR2PAMBLM | |
| SCHEMBL1419852 | 0.79 | CASP2 (0.51) | EPHX2DNM1CA1CA2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806350-B1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO INT BV (NL) | 2010-01-06 | — | — | EP | disclosed |
| EP-1806350-A2 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO International B.V. (NL) | 2007-07-11 | — | — | EP | disclosed |
| US-6652834-B2 | Tensioactive properties, long lasting activity in the blood pool | BRACCO INTERNATIONAL B.V. (NL) | 2003-11-25 | — | — | US | disclosed |
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | BRACCO INTERNATIONAL B.V. | 2002-07-25 | — | — | US | disclosed |
| US-6342598-B1 | BLOOD-POOL CONTRAST AGENTS OF OUTSTANDING LONG LIFE IN CIRCULATION | BRACCO INTERNATIONAL B.V. (NL) | 2002-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020098152-A1 | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents | SLC39A14, HAMP, PICALM | DGKA 2783/4885EPHX2 4596/4885DNM1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.